Posted by Michael Wonder on 22 Apr 2024
Sandoz confirms European Commission approval of Pyzchiva (ustekinumab), further strengthening immunology offering
22 April 2024 - EC approval based on robust development program confirming match to reference medicine in terms of safety, efficacy and quality.
Sandoz today announces that the European Commission has granted marketing authorisation for Pyzchiva (biosimilar ustekinumab), developed and registered by Samsung Bioepis.
